youtube_live
Q1 2026 earnings • released • EPS beat +4.76%
See resultschevron_right
CMPS:NASDAQ
Compass Pathways PLC
$10.37
arrow_downward
-2.35%(-0.25) 1D
$10.40
arrow_upward
+0.29% (+0.030)bedtimeAfter hours
Closed: May 15, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CMPS...
Open
$10.35
High
$10.69
Low
$10.04
Mkt. cap
1.40B
Avg. vol.
4.92M
Volume
3.13M
52-wk high
$11.28
52-wk low
$2.25
EPS
-$2.00
Beta
2.39
Shares outstanding
134.95M
No. of employees
156
News stories
From sources across the web
Profile
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine.
Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus.
Compass Pathways has entered partnerships with several independent psychedelic academic scientists, including Jason Wallach, Hamilton Morris, and Adam Halberstadt among others, to develop novel psychedelic drugs for potential medical use. Wikipedia
About Compass Pathways PLC
AI content may include mistakes. Learn more